Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abraxane, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Reyataz and Sustiva Franchise. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.
- Revenue in USD (TTM)44.38bn
- Net income in USD-5.08bn
- LocationBristol-Myers Squibb Co430 E 29th St Fl 14NEW YORK 10016-8367United StatesUSA
- Phone+1 (212) 546-4000
- Fax+1 (302) 655-5049